QOPI Reporting Registry (QCDR) Measures

PQRS Measures

2018 QCDR Measures List

Measure #

Measure

Measure Type

High Priority

NQF Measure #

QOPI5

Chemotherapy administered to patients with metastatic solid tumor with performance status of 3, 4, or undocumented (Lower Score - Better)

Process

N/A

N/A

QOPI11

Combination chemotherapy received within 4 months of diagnosis by women under 70 with AJCC stage IA (T1c) to III ER/PR negative breast cancer

Process

N/A

NQF Endorsed #0559

QOPI15

GCSF administered to patients who received chemotherapy for metastatic cancer (Lower Score - Better)

Process

N/A

NQF Endorsed #0326

QOPI16

Oncology: Treatment Summary Communication – Radiation Oncology

Process

N/A

NQF Endorsed #0381

QOPI17

External Beam Radiotherapy for Bone Metastases

Process

N/A

NQF Endorsed #1822

QPP 47

Care Plan

Process

Yes

NQF Endorsed #0326

QPP 67

Hematology: Myelodysplastic Syndrome (MDS) and Acute Leukemias: Baseline Cytogenetic Testing Performed on Bone Marrow

Process

No

NQF Endorsed #0377

QPP 69

Hematology: Multiple Myeloma: Treatment with Bisphosphonates

Process

No

NQF Endorsed #0380

QPP 70

Hematology: Chronic Lymphocytic Leukemia (CLL): Baseline Flow Cytometry

Process

No

NQF Endorsed #0379

QPP 102

Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patient

Process

Yes

NQF Endorsed #0389

QPP 104

Prostate Cancer: Adjuvant Hormonal Therapy for High Risk or Very High Risk Prostate Cancer

Process

No

NQF Endorsed #0390

QPP 130

Documentation of Current Medications in the Medical Record

Process

Yes

NQF Endorsed #00419

QPP 134

Preventive Care and Screening: Screening for Clinical Depression and Follow-Up Plan

Process

No

NQF Endorsed #00418

QPP 143

Oncology: Medical and Radiation - Pain Intensity Quantified

Process

Yes

NQF Endorsed #0384

QPP 226

Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention

Process

No

NQF Endorsed #0028

QPP 317

Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented     

Process

No

N/A

QPP 408

Opioid Therapy Follow-up Evaluation

Process

No

N/A

QPP 449

HER2 Negative or Undocumented Breast Cancer Patients Spared Treatment with HER2-Targeted Therapies

Process

Yes

NQF Endorsed #1857

QPP 450

Trastuzumab Received By Patients With AJCC Stage I (T1c) -  III And HER2 Positive Breast Cancer Receiving Adjuvant Chemotherapy

Process

Yes

NQF Endorsed #1858

QPP 451

KRAS Gene Mutation Testing Performed for Patients with Metastatic Colorectal Cancer who receive Anti-epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody Therapy

Process

No

NQF Endorsed #1859

QPP 452

Patients with Metastatic Colorectal Cancer and KRAS Gene Mutation Spared Treatment with Anti-epidermal Growth Factor Receptor (EGFR) Monoclonal Antibodies

Process

Yes

NQF Endorsed #1860

QPP 453

Proportion Receiving Chemotherapy in the Last 14 Days of Life   (Lower score - Better)

Process

Yes

NQF Endorsed #0210

QPP 456

Proportion Not Admitted To Hospice

Process

Yes

NQF Endorsed #0215

QPP 457

Proportion Admitted to Hospice for less than 3 days   (Lower score - Better)

Outcome

Yes

NQF Endorsed #0216

QPP 462

Bone Density Evaluation for Patients with Prostate Cancer and Receiving Androgen Therapy

Process

No

N/A

 Click to view the full 2018 measure specifications